Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication
Source: Streetwise Reports  (2/21/20)
Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESOâ„¢ drug for management of moderate to severe pain. More >

FDA Approval of Biopharma's Pain Drug Expected This Year
Source: Streetwise Reports  (2/19/20)
The reasons a green light is anticipated and how it relates to the closing of Avenue Therapeutics' pending acquisition are discussed in an H.C. Wainwright & Co. report. More >

Viela Bio Shares Trade Higher After Analyst Issues 'Buy' Recommendation
Source: Streetwise Reports  (2/18/20)
Shares of Viela Bio Inc. rose 20% after an analyst at H.C. Wainwright & Co. initiated coverage of the stock. More >

Life Sciences Firm Contracts with Philippines Distributor
Source: Streetwise Reports  (2/18/20)
This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product. More >

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates
Source: Streetwise Reports  (2/14/20)
Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. More >

vTv Therapeutics' Shares Open 80% Higher on Phase 2 Type 1 Diabetes Trial Data
Source: Streetwise Reports  (2/10/20)
Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. More >

Biopharma Has Three 2020 Shots on Goal in Pediatric Liver Diseases
Source: Streetwise Reports  (2/8/20)
The events in that trio are presented in a ROTH Capital Partners report. More >

Cortexyme Secures $125M Private Placement Capital to Advance Clinical Development
Source: Streetwise Reports  (2/6/20)
Shares of Cortexyme Inc. traded 20% higher after the company reported that it secured an additional $125M in capital from a private placement. The firm intends to use the proceeds to fund current Alzheimer's clinical trials and ongoing operations. More >

Vivus Shares Climb 50% Higher on sNDA Approval for Exocrine Pancreatic Insufficiency Drug
Source: Streetwise Reports  (2/5/20)
Shares of Vivus traded higher after the FDA approved the company's supplemental New Drug Application for an improved formulation of PANCREAZE® (pancrelipase) for use in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions. More >

Understanding Fortress Biotech
Source: Daniel Carlson for Streetwise Reports  (2/5/20)
Daniel Carlson of Tailwinds Research takes a close look at what he calls a "great value opportunity," with a focus on subsidiary Avenue Therapeutics. More >

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data
Source: Streetwise Reports  (2/3/20)
Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. More >

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'
Source: Streetwise Reports  (1/31/20)
The compelling aspects of this life sciences story are presented in a Dawson James report. More >

Syndax Pharma Shares Rise on $35M Capital Raise, Credit Line and Positive Phase 1/2 Leukemia Trial Results
Source: Streetwise Reports  (1/31/20)
Syndax Pharmaceuticals' shares traded 30% higher after the company reported it expects to raise $35 million from a common stock offering from five institutional investors and secured a $30 million non-dilutive term loan facility. More >

CEO Reviews Life Sciences Firm's Year of 'Exceptional Accomplishment'
Source: Streetwise Reports  (1/30/20)
The company makes progress getting its products approved and sold in more countries. More >

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch
Source: Streetwise Reports  (1/30/20)
Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. More >

Two Approvals Underscore Biotech's Pipeline Quality
Source: Streetwise Reports  (1/29/20)
The green lights and their implications are discussed in an H.C. Wainwright & Co. report. More >

California Gold: Two U.S. Hemp Revenue Streams Coming Online This Quarter
Source: Peter Epstein for Streetwise Reports  (1/29/20)
Peter Epstein of Epstein Research discusses recent developments at the company. More >

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data
Source: Streetwise Reports  (1/28/20)
Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. More >

Inovio Pharma Awarded $9M Development Grant for Coronavirus Vaccine
Source: Streetwise Reports  (1/27/20)
Inovio Pharmaceuticals' shares rose 30%, setting a new 52-week high price, after the firm reported it received a grant of up to $9 million to develop a vaccine against the coronavirus. More >

My Prediction for a Market Top in October Was Perhaps Left but Not Wrong
Source: Bob Moriarty for Streetwise Reports  (1/26/20)
Bob Moriarty of 321gold reflects on how government actions in the financial and public health spheres will pop market bubbles. More >

Neurotrope's Shares Double on Phase 2 Alzheimer's Study Data and $2.7 Million NIH Grant
Source: Streetwise Reports  (1/22/20)
Neurotrope's shares traded higher today after reporting results from its Phase 2 "203" clinical trial of Byrostatin-1 for treatment of moderately severe to severe Alzheimer's patients. The firm has also been awarded a $2.7 million grant from the National Institutes of Health to conduct additional clinical research for patients with advanced Alzheimer's disease. More >

Biopharma Shows 'Good Start to 2020 News Flow'
Source: Streetwise Reports  (1/21/20)
The two developments that already took place this year are addressed in an H.C. Wainwright & Co. report. More >

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug
Source: Streetwise Reports  (1/21/20)
Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. More >

InMed Shares Trade Up 25% After Becoming First to Advance Cannabinol into Clinical Trials
Source: Streetwise Reports  (1/20/20)
InMed Pharmaceuticals shares traded 25% higher after reporting that it is the first to advance cannabinol into therapeutic clinical trials. More >

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation
Source: Streetwise Reports  (1/16/20)
Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. More >